Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
17 beta-estradiol + progesterone
- Development stage
- Unknown
- Lead developer
- TherapeuticsMD
- Modality
- Small Molecules
- Administration
- Transdermal, Oral
01
Overview
This hormone replacement therapy (HRT) regimen, evaluated by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), consists of transdermal 17 beta-estradiol and oral micronized progesterone. It is specifically investigated for the treatment of premature ovarian insufficiency (POI) in female adolescents aged 11 to 19 years. The regimen aims to mimic physiological hormone levels to induce puberty or provide maintenance therapy, thereby mitigating long-term risks associated with hypoestrogenism, such as osteoporosis, cardiovascular disease, and psychological distress. The 17 beta-estradiol is administered via a transdermal patch with escalating doses (25 to 100 micrograms), while progesterone is added cyclically (100 mg/day for 12 days/month) to protect the endometrium and induce withdrawal bleeding.
- Other names
- 17 beta-estradiolestradiolprogesteroneHormone Replacement TherapyHRT
02
Targets
PR (Progesterone receptor)ESR2 (ERβ)ESR1 (ERα)
Beyond the preview
Go deeper on 17 beta-estradiol + progesterone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 17 beta-estradiol + progesterone.